Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
54.64
+0.19 (0.35%)
At close: Aug 31, 2026, 4:00 PM EDT
54.51
-0.13 (-0.24%)
Pre-market: Sep 1, 2026, 8:53 AM EDT
Exelixis Market Cap
Exelixis has a market cap or net worth of $13.54 billion as of September 1, 2026. Its market cap has increased by 34.40% in one year.
Market Cap
13.54B
Enterprise Value
12.32B
1-Year Change
34.40%
Ranking
Category
Stock Price
$54.64
ChartMarket Cap Chart
Since April 17, 2000, Exelixis's market cap has increased from $630.80M to $13.54B, an increase of 2,046.29%. That is a compound annual growth rate of 12.32%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 31, 2026 | 13.54B | 15.21% |
| Dec 31, 2025 | 11.75B | 23.57% |
| Dec 31, 2024 | 9.51B | 27.47% |
| Dec 29, 2023 | 7.46B | 44.19% |
| Dec 30, 2022 | 5.17B | -10.54% |
| Dec 31, 2021 | 5.78B | -7.11% |
| Dec 31, 2020 | 6.23B | 16.30% |
| Dec 31, 2019 | 5.35B | -8.96% |
| Dec 31, 2018 | 5.88B | -34.61% |
| Dec 29, 2017 | 8.99B | 110.58% |
| Dec 30, 2016 | 4.27B | 233.29% |
| Dec 31, 2015 | 1.28B | 355.89% |
| Dec 31, 2014 | 281.10M | -75.11% |
| Dec 31, 2013 | 1.13B | 34.59% |
| Dec 31, 2012 | 839.00M | 36.62% |
| Dec 30, 2011 | 614.10M | -31.37% |
| Dec 31, 2010 | 894.80M | 13.07% |
| Dec 31, 2009 | 791.40M | 49.29% |
| Dec 31, 2008 | 530.10M | -41.23% |
| Dec 31, 2007 | 902.00M | 4.64% |
| Dec 29, 2006 | 862.00M | 10.08% |
| Dec 30, 2005 | 783.10M | 10.19% |
| Dec 31, 2004 | 710.70M | 41.83% |
| Dec 31, 2003 | 501.10M | 9.05% |
| Dec 31, 2002 | 459.50M | -44.16% |
View and export this data all the way back to 2000. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ascendis Pharma | 17.27B |
| Jazz Pharmaceuticals | 16.27B |
| BridgeBio Pharma | 14.97B |
| BioMarin Pharmaceutical | 12.63B |
| Madrigal Pharmaceuticals | 12.48B |
| Corcept Therapeutics | 12.25B |
| Halozyme Therapeutics | 12.09B |
| Arrowhead Pharmaceuticals | 11.64B |